These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Statin-associated psychiatric adverse events: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting. Tuccori M; Lapi F; Testi A; Coli D; Moretti U; Vannacci A; Motola D; Salvo F; Rivolta AL; Blandizzi C; Mugelli A; Del Tacca M Drug Saf; 2008; 31(12):1115-23. PubMed ID: 19026028 [TBL] [Abstract][Full Text] [Related]
4. Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study. Golomb BA; Kwon EK; Koperski S; Evans MA Drug Saf; 2009; 32(8):649-61. PubMed ID: 19591530 [TBL] [Abstract][Full Text] [Related]
5. Statin-associated muscle-related adverse effects: a case series of 354 patients. Cham S; Evans MA; Denenberg JO; Golomb BA Pharmacotherapy; 2010 Jun; 30(6):541-53. PubMed ID: 20500044 [TBL] [Abstract][Full Text] [Related]
6. Mood, Personality, and Behavior Changes During Treatment with Statins: A Case Series. Cham S; Koslik HJ; Golomb BA Drug Saf Case Rep; 2016 Dec; 3(1):1. PubMed ID: 27747681 [TBL] [Abstract][Full Text] [Related]
7. Fluvastatin and hepatic reactions: a signal from spontaneous reporting in Italy. Conforti A; Magro L; Moretti U; Scotto S; Motola D; Salvo F; Ros B; Leone R Drug Saf; 2006; 29(12):1163-72. PubMed ID: 17147462 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys. Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758 [TBL] [Abstract][Full Text] [Related]
9. An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Figueiras A; Herdeiro MT; Polónia J; Gestal-Otero JJ JAMA; 2006 Sep; 296(9):1086-93. PubMed ID: 16954488 [TBL] [Abstract][Full Text] [Related]
10. Monitoring drug safety in Astrakhan, Russia. Kirilochev OO; Dorfman IP; Umerova AR Int J Risk Saf Med; 2015; 27 Suppl 1():S33-4. PubMed ID: 26639700 [TBL] [Abstract][Full Text] [Related]
11. Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase. Edwards IR; Star K; Kiuru A Drug Saf; 2007; 30(6):515-25. PubMed ID: 17536877 [TBL] [Abstract][Full Text] [Related]
12. HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre. de Langen JJ; van Puijenbroek EP Neth J Med; 2006 Oct; 64(9):334-8. PubMed ID: 17057271 [TBL] [Abstract][Full Text] [Related]
13. Comparing patients' and healthcare professionals' ADR reports after media attention: the broadcast of a Dutch television programme about the benefits and risks of statins as an example. van Hunsel F; Passier A; van Grootheest K Br J Clin Pharmacol; 2009 May; 67(5):558-64. PubMed ID: 19552751 [TBL] [Abstract][Full Text] [Related]
14. Texting-Based Reporting of Adverse Drug Reactions to Ensure Patient Safety: A Feasibility Study. Vergeire-Dalmacion G; Castillo-Carandang NT; Juban NR; Amarillo ML; Tagle MP; Baja ES JMIR Public Health Surveill; 2015; 1(2):e12. PubMed ID: 27227130 [TBL] [Abstract][Full Text] [Related]
15. Hepatic adverse drug reactions: a case/non-case study in Italy. Motola D; Vargiu A; Leone R; Cocci A; Salvo F; Ros B; Meneghelli I; Venegoni M; Cutroneo PM; Vaccheri A; Velo G; Montanaro N Eur J Clin Pharmacol; 2007 Jan; 63(1):73-9. PubMed ID: 17119945 [TBL] [Abstract][Full Text] [Related]
16. A comprehensive intervention for adverse drug reactions identification and reporting in a Pediatric Emergency Department. Morales Ríos O; Jasso Gutiérrez L; Talavera JO; Téllez-Rojo MM; Olivar López V; Garduño Espinosa J; Muñoz Hernández O Int J Clin Pharm; 2016 Feb; 38(1):80-7. PubMed ID: 26499501 [TBL] [Abstract][Full Text] [Related]
17. Pharmacy-coordinated program that encourages physician reporting of adverse drug reactions. Gilroy GW; Scollins MJ; Gay CA; Harry DJ; Giannuzzi DF Am J Hosp Pharm; 1990 Jun; 47(6):1327-33. PubMed ID: 2368726 [TBL] [Abstract][Full Text] [Related]
18. Media attention and the influence on the reporting odds ratio in disproportionality analysis: an example of patient reporting of statins. van Hunsel F; van Puijenbroek E; de Jong-van den Berg L; van Grootheest K Pharmacoepidemiol Drug Saf; 2010 Jan; 19(1):26-32. PubMed ID: 19953500 [TBL] [Abstract][Full Text] [Related]
19. Physicians' attitudes and adverse drug reaction reporting : a case-control study in Portugal. Herdeiro MT; Figueiras A; Polónia J; Gestal-Otero JJ Drug Saf; 2005; 28(9):825-33. PubMed ID: 16119975 [TBL] [Abstract][Full Text] [Related]
20. Adverse drug reactions reporting by undergraduate medical students in a tertiary care teaching hospital of India: Content and quality analysis in comparison to physician reporting. Patel PB; Patel TK; Anturlikar S; Khatun S; Bhabhor P; Saurabh MK Perspect Clin Res; 2017; 8(3):137-144. PubMed ID: 28828309 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]